Today (Wednesday 30 January), the pharmaceutical company Roche has announced they have ended their phase III clinical trial of the potential Alzheimer’s drug, crenezumab, which was designed to treat people in the early stages of Alzheimer’s disease.
Today (Wednesday 30 January), the pharmaceutical company Roche has announced they have ended their phase III clinical trial of the potential Alzheimer’s drug, crenezumab, which was designed to treat people in the early stages of Alzheimer’s disease.
Dr David Reynolds, Chief Scientific Officer from Alzheimer’s Research UK, said:
“While it’s disappointing to see any Alzheimer’s trial ended early, the full study results can still provide important insights that could shape future trials to slow or stop Alzheimer’s disease.
“Amyloid remains a key player in Alzheimer’s disease and while a number of ongoing trials are investigating this protein, it’s also important to widen the number of approaches being explored to treat the disease. Alzheimer’s Research UK continues to work with drug discovery experts to strengthen and diversify the pipeline of potential Alzheimer’s treatments in clinical trials to maximise our chances of finding effective new drugs.
“Compared to other health conditions like cancer, research into the diseases that cause dementia have been vastly underfunded. We remain committed to delivering a life-changing dementia treatment and are calling for long-term sustained investment from both pharmaceutical companies, and government to deliver breakthroughs for people with dementia.”
Ends
For further information, or to speak with Dr David Reynolds, please contact Ed Pinches, Science Media Officer at Alzheimer’s Research UK on 0300 111 5 666, or email press@alzheimersresearchuk.org
Notes to editors:
· Our animation “What is dementia?” explains the essentials of dementia and the diseases that cause ithttps://www.youtube.com/watch?
· Alzheimer’s Research UK is the UK’s leading charity specialising in finding preventions, treatments and a cure for dementia.
· To help make breakthroughs possible, donate today by visiting www.alzheimersresearchuk.org or calling 0300 111 5555.
· We are currently supporting pioneering dementia research projects worth over £31 million in leading Universities across the UK.
· How can we challenge perceptions of dementia using only an orange? Find out more at www.alzheimersresearchuk.org/
